Providers and insurers need to do a better job of reaching patients and employers to help private accountable care organizations achieve lower costs and higher quality, according to physician executives at four large health insurance companies.
Drug giant AstraZeneca was denied approval of a diabetes drug combination treatment by U.S. regulators, citing the need for more clinical information.
Genentech, the maker of Avastin and other pricey cancer drugs, paid physicians and teaching hospitals more than any other drug or device company did in 2014, according to data published last week on the CMS' Open Payments website.
The federal government is launching a very different kind of cancer study that will assign patients drugs based on what genes drive their tumors rather than the type.
Medicare shelled out more than $103 billion on prescription drugs in 2013, raising questions about why the government pays so much for brand-name pharmaceuticals and how physicians prescribe drugs for their patients.
Merck & Co. said preliminary results of a post-market study of its diabetes drug Januvia showed no increase in hospitalization compared with patients who did not use the drug.
An advisory panel to the U.S. Food and Drug Administration voted Tuesday to recommend the agency require drugmaker AstraZeneca to change the labeling of its diabetes medication Onglyza to add safety information to reflect a heightened risk for heart failure associated with its use.
Lawyers say the suit against AstraZeneca and Ranbaxy has yielded the first jury decision in a so-called pay-for-delay case since a U.S. Supreme Court decision made it easier to challenge such agreements under federal antitrust law.
Drugmaker GlaxoSmithKline was fined $492 million on Friday for bribing doctors in China, the biggest such penalty ever imposed by a Chinese court.
Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, improve its profit forecast and top analysts' expectations.
The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.